MITSUBISHI TANABE PHARMA CORPORATION

English German


LEARN ABOUT HIT
What is HIT?
What causes HIT?
What are the complications?
When does HIT occur?
THE HIT PATIENT
Who is the patient?
When to suspect HIT
Estimating the probability
4Ts
After cardiac surgery
Laboratory testing for HIT
Managing the HIT patient
The ICU patient
Treatment options
Ask the Expert
RESOURCES
Whats New
Bulletins
Further Information
ABOUT ARGATROBAN
Introduction
Argatroban
Key features
Differentiation
Patient benefits
How does it work?
Clinical efficacy
Safety profile
Dosage guidelines
Dosage calculator
Preparation
References
SPC
Austria
Denmark
Germany
Iceland
Italy
The Netherlands
Norway
Sweden
PIL
Austria
Denmark
Germany
Iceland
Italy
The Netherlands
Norway
Sweden
Ordering
FAQs
Use in dialysis
CONTACT
Europe
Austria
Germany
Sweden
Denmark
Norway
Iceland
Italy
The Netherlands
External sites

Click for SPC

Healthcare

Site map / Terms of Use

© Mitsubishi Pharma Europe Ltd 2008